Surgical robot startup Abrobo gets US$14m cash transfusion in Series A

According to Frost & Sullivan, the number of robot-assisted vascular interventional surgeries is projected to hit 7 million to 10 million every year.

Abrobo (爱博医疗机器人), a Shenzhen-based surgical robot developer, has netted 100 million yuan (US$14 million) in a Series A round of funding, Chinese media reported today.

The round was led by Guozhong Capital, with participation from existing shareholders Lenovo Capital and Long Hill Capital.

Proceeds from the latest round will be used to accelerate the clinical trial of general endovascular robots, build a technical platform for vascular interventional robotics and recruit more talent.

Founded in June 2020, Abrobo mainly produces neurointerventional surgical robot and general endovascular robot that accommodate multipel surgical needs.

The company has filed 368 domestic and overseas patent applications and was granted 135 patents.

Vascular interventional surgical robot has been a fast-expanding category of the surgical robot family in China, amid an aging population and growing incidence of chronic diseases.

Currently, vascular interventional surgical robot is primarily applied in three types of surgical procedures, including percutaneous coronary intervention (PCI), neurointervention, and peripheral vascular intervention.

According to Frost & Sullivan, the number of robot-assisted vascular interventional surgeries is projected to hit 7 million to 10 million every year.

The high precision, entry barrier and levels of radiation associated with endovascular surgeries have made it challenging to perform these procedures.

Traditionally, surgeons presiding over endovascular operations need to work close to X-ray tubes, exposing them to radiation, jeopardizing their health and cutting short their careers.

The appearance of vascular interventional surgical robot has solved these pain points through a master-slave mechanism, where doctors are exposed to a lesser risk of radiation and the safety of the surgeries also improves.

Avatar photo
Ni Tao

Ni Tao is the founder and editor-in-chief of cnrobopedia. Prior to cnrobopedia, he had a full decade of experience with a major state-run English-language newspaper as a tech reporter and opinion writer. He is also a communications specialist, having provided consultancy services to established firms like Siemens, Philips, ABinBev, Diageo, Group (Nasdaq: TCOM, HK: 9961), Jianpu Technology (NYSE: JT) and a handful of domestic startups. A graduate of Fudan University, he writes widely about China's business and tech scenes and other topics for global publications including South China Morning Post, SupChina, The Diplomat, CGTN, Banking Technology, among others, and tries to impart his experience to students at Fudan University Journalism School, where he is a part-time lecturer. When he's not writing about robotics, you can expect him to be on his beloved Yanagisawa saxophones, trying to play some jazz riffs, often in vain and occasionally against the protests of an angry neighbor. Get in touch with him by dropping a line at

Articles: 675